Mithilesh Sahu, Mithun Bhowmick, Jagdish Rathi


The aim of the present work is to study the preformulation parameters for Transdermal drug delivery system. The objective of Preformulation study is to generic information useful to the formulater in developing stable and bioavailable dosage form. The use of Preformulation parameter maximizes the chances in formulation an acceptable, safe, efficacious and stable product and at the same time provide the basis for optimization of the drug product quality. Administration of conventional tablets of repaglinide has been reported to exhibit fluctuations in plasma drug levels, resulting either in manifestation of side effects or reduction in drug concentration at the receptor sites also, the maintenance of a constant plasma concentration of a anti-diabetic drug is important in ensuring the desired therapeutic response, again since the half life of repaglinide is  01 hour hence multiple doses of the drug are needed to maintain a constant plasma concentration for a good therapeutic response, and improve patient compliance, hence the objective of the study was made to develop controlled release Transdermal Drug Delivery System of repaglinide using polymer like Eudragit RS 100, Eudragit RL 100 and HPMC, which will controlled the release of drug, increasing the bioavailability of the drug and thus decreasing the dosing frequency of the drug. The Preformulation studies were carried out in terms of test for identification (physical appearance, melting point, and uv spectrophotometer), solubility profile, determination of partition coefficient and quantitative estimation of drug. All the observation and results showed that the repaglinide could serve as suitable candidate for Transdermal drug delivery system that may improve the bioavailability.

Keywords: Transdermal, Repaglinide, Preformulation, Half Life, bioavailability


Vyas SP, Roop RK. Controlled drug delivery concepts and advances. New Delhi: Vallabh Prakash publishers; 2002.

Chien YW. Transdermal therapeutic systems. In: Robinson JR, Lee V. H. editors. Controlled drug delivery: Fundamentals and applications. New York: Marcel Dekker; 1987, p. 524-549.

Tripathi KD. Insulin, oral hypoglycemics and glucagons, in: Essentials of Medical Pharmacology. 6th edition, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 2008: 235.

Dornhorst Anne. Insulinotropic meglitinide analogues; New drug classes. The Lancet 2001; 358:1709-16

Ambavane V, Patil R and Aina SS. Repaglinide: A short acting insulin secretogogue for post prandial hyperglycaemia. J Postgrad Med 2002; 48:246-48.

Repaglinide,The free enclycopedia : ""

Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 Diabetes Mellitus (T2DM) therapeutic landscape. Supplement to the Journal of Family Practice, January 2007: S1-S12.

Grant P and Dashora U. The incretin effect and the use of Dipeptidy peptidase- 4 inhibitors. Int J Diab Dev Ctries September 2007; 27(3): 65-8.

Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 2006; 32:113-20.

Brunton LL, Lazo JS and Parker KL. Eds. Goodman & Gilman’s – The Pharmacological Basis of Therapeutics. 11th edition. Mc Graw-Hill, medical publishing division; 2006: 1637-8, 1867.

Sweetman SC. editor. Martindale, The Complete Drug Reference. 35th edition: 415.

Gandhimathi M, Ravi TK, and Renu SK. Determination of Repaglinide in Pharmaceutical Formulations by HPLC with UV Detection. Analytical Sciences 2003; 19: 1675-77.

Pharmaceutics- The science of Dosage Form Design by M. E. Aulton. (2nd edition): pg.113

The Science & Practice of Pharmacy by Remington.(19th edition): pg.1447

The Theory & Practice of Industrial Pharmacy by Leon Lachman, Herbet A. Lieberman, Joseph L. Kaing.(3rd edition): pg.171

Modern Pharmaceutics by G. S. Banker & C. T. Rhodes. (4th edition): pg.211

Pharmaceutical Dosage Forms by Leon Lachman, H. A. Lieberman; Vol.1: pg.1

Pharmaceutical Dosage Forms & Delivery Systems by H.C. Ansel, L.V.Allen, N.G.Popvich; (7th edition): pg.64

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

ISSN: 2250-1177  This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.